<DOC>
	<DOCNO>NCT00635427</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety every week dose Gene-Activated® human glucocerebrosidase ( GA-GCB , velaglucerase alfa ) intravenously patient type 1 Gaucher disease .</brief_summary>
	<brief_title>An Open-Label Extension Study GA-GCB ERT Patients With Type 1 Gaucher Disease</brief_title>
	<detailed_description>Type 1 Gaucher disease , common form , account 90 % case involve CNS . Typical manifestation type 1 Gaucher disease include hepatomegaly , splenomegaly , thrombocytopenia , bleed tendency , anemia , hypermetabolism , skeletal pathology , growth retardation , pulmonary disease , decrease quality life . Gene-Activated® human glucocerebrosidase ( GA-GCB , velaglucerase alfa ) produce continuous human cell line use proprietary gene-activation technology identical amino acid sequence naturally occur human enzyme . GA-GCB contains terminal mannose residue target enzyme macrophages-the primary target cell Gaucher disease . This study design determine long-term safety GA-GCB men , woman , child Type 1 Gaucher disease .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>1 . The patient complete study TKT032 TKT034 , study HGTGCB039 . 2 . Female patient childbearing potential must agree use medically acceptable method contraception time study must negative result pregnancy test perform time enrollment require throughout participation study . 3 . Male patient must agree use medically acceptable method contraception time study report partner 's pregnancy investigator . 4 . The patient , patient 's parent ( ) legal guardian ( ) provide write informed consent approve Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) . 5 . The patient must sufficiently cooperative participate clinical study judge Investigator 1 . The patient receive treatment nonGaucher diseaserelated investigational drug device within 30 day prior study entry ; use study permit . 2 . The patient pregnant lactating . 3 . The patient , patient 's parent ( ) , patient 's legal guardian ( ) is/are unable understand nature , scope , possible consequence study . 4 . The patient significant comorbidity ( y ) might affect study data confound study result ( e.g. , malignancy , primary biliary cirrhosis , autoimmune liver disease , etc. ) . 5 . The patient unable comply protocol , e.g. , clinically relevant medical condition make implementation protocol difficult , uncooperative attitude , unable return safety evaluation , otherwise unlikely complete study , determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>VPRIV</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>Gaucher disease</keyword>
	<keyword>glucocerebrosidase</keyword>
	<keyword>beta-glucocerebrosidase</keyword>
	<keyword>Acid beta-glucocerebrosidase</keyword>
	<keyword>glucosylceramidase</keyword>
	<keyword>D-glucosyl-N-acylsphingosine glucohydrolase</keyword>
	<keyword>gene activation</keyword>
	<keyword>human</keyword>
</DOC>